MCID: BPL002
MIFTS: 49

Bipolar I Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 74 15 17 71

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 34 296.50
SNOMED-CT 67 49468007
UMLS 71 C0236773 C0853193

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to depression and endogenous depression. An important gene associated with Bipolar I Disorder is GADL1 (Glutamate Decarboxylase Like 1), and among its related pathways/superpathways are G-Beta Gamma Signaling and Beta-Adrenergic Signaling. The drugs Coal tar and Oxcarbazepine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Bipolar I disorder (BD-I; pronounced "type one bipolar disorder") is a type of bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 197)
# Related Disease Score Top Affiliating Genes
1 depression 30.9 SLC6A4 HTR2C HTR2A HTR1A BDNF
2 endogenous depression 30.5 SLC6A4 HTR2A HTR1A COMT BDNF
3 social phobia 30.4 SLC6A4 HTR1A DRD2 COMT BDNF
4 early-onset schizophrenia 30.3 DRD2 DRD1 BDNF
5 constipation 30.3 SLC6A4 HTR2A HTR1A BDNF
6 conduct disorder 30.2 SLC6A4 DRD4 DRD2 COMT
7 cyclothymic disorder 30.2 HTR2A DRD4 DRD2 COMT
8 dysthymic disorder 30.1 SLC6A4 HTR2A HTR1A BDNF
9 tardive dyskinesia 30.1 HTR2A DRD3 DRD2 COMT
10 drug dependence 30.0 SLC6A4 DRD3 DRD2 DRD1 BDNF
11 melancholia 29.9 SLC6A4 HTR2A HTR1A BDNF
12 cannabis dependence 29.9 NRG1 DRD2 COMT
13 obsessive-compulsive personality disorder 29.9 SLC6A4 HTR2A DRD3 COMT
14 hyperprolactinemia 29.8 HTR2C HTR2A DRD4 DRD2
15 sleep apnea 29.8 SLC6A4 HTR2C HTR2A BDNF
16 agoraphobia 29.8 SLC6A4 HTR2A HTR1A COMT BDNF
17 amnestic disorder 29.8 HTR1A GAD1 DRD2 DRD1 BDNF
18 neuroleptic malignant syndrome 29.8 HTR2A HTR1A DRD3 DRD2 DRD1
19 trichotillomania 29.7 DRD4 DRD3 DRD2
20 substance abuse 29.6 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
21 borderline personality disorder 29.6 SLC6A4 HTR2C HTR2A HTR1A DRD2 COMT
22 generalized anxiety disorder 29.6 SLC6A4 HTR2C HTR2A HTR1A DRD2 COMT
23 alcohol use disorder 29.5 SLC6A4 HTR2C HTR2A HTR1A DRD3 DRD2
24 schizotypal personality disorder 29.5 NRG1 DTNBP1 DRD4 DRD2 COMT CACNA1C
25 intermittent explosive disorder 29.5 SLC6A4 HTR2C HTR2A HTR1A DRD2 COMT
26 post-traumatic stress disorder 29.4 SLC6A4 NRG1 HTR2A HTR1A DRD2 COMT
27 dystonia 29.3 HTR2A DRD3 DRD2 DRD1 COMT BDNF
28 anxiety 29.3 SLC6A4 HTR2C HTR2A HTR1A GAD1 DRD4
29 mental depression 29.3 SLC6A4 HTR2C HTR2A HTR1A DRD4 DRD3
30 substance dependence 29.2 SLC6A4 DTNBP1 DRD4 DRD3 DRD2 DRD1
31 personality disorder 29.2 SLC6A4 HTR2C HTR2A HTR1A DRD4 DRD3
32 cocaine dependence 29.2 SLC6A4 HTR2C HTR2A DRD3 DRD2 DRD1
33 tobacco addiction 29.2 SLC6A4 HTR2A DRD4 DRD3 DRD2 DRD1
34 sexual disorder 29.1 SLC6A4 HTR2C HTR2A HTR1A DRD4 DRD3
35 bipolar disorder 29.1 TIMELESS SLC6A4 PER3 NRG1 HTR2C HTR2A
36 schizoaffective disorder 28.9 TIMELESS SLC6A4 PER3 HTR2A HTR1A DTNBP1
37 obsessive-compulsive disorder 28.9 SLC6A4 HTR2C HTR2A HTR1A DRD4 DRD3
38 delusional disorder 28.9 HTR2C HTR2A HTR1A DRD4 DRD3 DRD2
39 alcohol dependence 28.9 SLC6A4 HTR2C HTR2A HTR1A GAD1 DRD4
40 schizophreniform disorder 28.8 NRG1 HTR2A DTNBP1 DRD4 DRD3 DRD2
41 impulse control disorder 28.8 SLC6A4 HTR2A HTR1A DRD4 DRD3 DRD2
42 panic disorder 28.8 SLC6A4 HTR2C HTR2A HTR1A GAD1 DRD4
43 attention deficit-hyperactivity disorder 28.7 SLC6A4 HTR2C HTR2A HTR1A GAD1 DRD4
44 mood disorder 28.4 SLC6A4 PER3 NRG1 HTR2C HTR2A HTR1A
45 migraine with or without aura 1 28.1 SLC6A4 HTR2C HTR2A HTR1A DRD4 DRD3
46 major depressive disorder 28.0 SLC6A4 PER3 HTR2C HTR2A HTR1A GAD1
47 psychotic disorder 27.9 SLC6A4 NRG1 HTR2C HTR2A HTR1A GAD1
48 alzheimer disease 27.9 SLC6A4 NRG1 HTR2A HTR1A DRD4 DRD3
49 schizophrenia 27.9 SLC6A4 NRG1 HTR2C HTR2A HTR1A GAD1
50 autism spectrum disorder 27.7 SLC6A4 NRG1 HTR2C HTR2A GAD1 DRD4

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 ANK3 ARNTL BDNF CACNA1C COMT DRD1
2 homeostasis/metabolism MP:0005376 10.13 ARNTL BDNF CACNA1C COMT DRD1 DRD2
3 digestive/alimentary MP:0005381 9.91 BDNF DRD1 DRD2 DRD3 GAD1 HTR2A
4 integument MP:0010771 9.91 ARNTL BDNF CACNA1C DRD1 DRD2 DTNBP1
5 nervous system MP:0003631 9.86 ANK3 ARNTL BDNF CACNA1C COMT DRD1
6 muscle MP:0005369 9.76 ARNTL CACNA1C DRD1 DRD2 DTNBP1 HTR2A
7 respiratory system MP:0005388 9.17 ANK3 ARNTL BDNF COMT DRD1 DRD2

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Coal tar Approved Phase 4 8007-45-2
2
Oxcarbazepine Approved Phase 4 28721-07-5 34312
3
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
4
Ethanol Approved Phase 4 64-17-5 702
5
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
6
Ziprasidone Approved Phase 4 146939-27-7 60854
7
Topiramate Approved Phase 4 97240-79-4 5284627
8
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
9
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
10
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
11
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
12
Infliximab Approved Phase 4 170277-31-3
13
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
14
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
15
Choline Approved, Nutraceutical Phase 4 62-49-7 305
16 Gastrointestinal Agents Phase 4
17 Antiemetics Phase 4
18 Sodium Channel Blockers Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Hormones Phase 4
21 Calcium, Dietary Phase 4
22 calcium channel blockers Phase 4
23 Anti-Obesity Agents Phase 4
24 Appetite Depressants Phase 4
25 Hypoglycemic Agents Phase 4
26 Cyclooxygenase 2 Inhibitors Phase 4
27 Hypolipidemic Agents Phase 4
28 Lipid Regulating Agents Phase 4
29 Antimetabolites Phase 4
30 Lecithin Phase 4
31 Cytidine Diphosphate Choline Phase 4
32 Narcotics Phase 4
33 Narcotic Antagonists Phase 4
34 Dermatologic Agents Phase 4
35 Antirheumatic Agents Phase 4
36 Analgesics, Non-Narcotic Phase 4
37 Anticonvulsants Phase 4
38 Quetiapine Fumarate Phase 4 111974-72-2
39
Calcium Nutraceutical Phase 4 7440-70-2 271
40
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
41
Brexpiprazole Approved, Investigational Phase 3 913611-97-9 11978813
42
Haloperidol Approved Phase 3 52-86-8 3559
43
Loxapine Approved Phase 3 1977-10-2 3964
44
Asenapine Approved Phase 3 65576-45-6, 85650-56-2 3001386
45
Clozapine Approved Phase 3 5786-21-0 2818
46
Promethazine Approved, Investigational Phase 3 60-87-7 4927
47
Lorazepam Approved Phase 3 846-49-1 3958
48
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
49
Histamine Approved, Investigational Phase 3 51-45-6 774
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 221)
# Name Status NCT ID Phase Drugs
1 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
2 ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
3 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
4 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
5 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed Completed NCT00034580 Phase 4 olanzapine;risperidone
6 A Phase IV, Multi-Center, Open-Label, Safety and Effectiveness Study of Extended-Release Carbamazepine in the Treatment of Mania in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder. Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
7 Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed NCT00190892 Phase 4 olanzapine;carbamazepine
8 A Double-Blind Placebo Controlled Trial of Divalproex and Olanzapine in Bipolar I Disorder, Mixed Episode Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
9 A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia Completed NCT00982020 Phase 4 Olanzapine
10 Treatment of Primary Mood Disorders in the Comorbidly Ill Completed NCT00178061 Phase 4
11 A Multicenter, Double-blind, Study of the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
12 The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
13 Efficacy of Aripiprazole in Combination With Lithium or Valproate in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients Partially Nonresponsive to Lithium or Valproate Monotherapy Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
14 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
15 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
16 Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
17 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
18 An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
19 Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression: Role of Inflammation and Kynurenine Pathway Biomarkers Completed NCT01479829 Phase 4 ESC + CBX;ESC + PBO.;ESC+CBX
20 Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
21 Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
22 Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents Completed NCT00393978 Phase 4 Quetiapine and placebo;Quetiapine and Topiramate
23 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
24 An Open-Label, Flexible-Dose Trial of the Safety and Efficacy of Geodon in Non-Rapid-Cycling Bipolar II Patients With Major Depression Completed NCT00237666 Phase 4 Ziprasidone
25 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
26 A Double-Blind, Placebo-Controlled Trial of Seroquel for the Treatment of Dysphoric Hypomania in Bipolar II Patients Completed NCT00186043 Phase 4 Quetiapine/Seroquel;Placebo
27 Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
28 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
29 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
30 An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators Completed NCT00463580 Phase 4 Infliximab;Placebo
31 A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
32 A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole Active, not recruiting NCT03881449 Phase 4
33 Phase IV Study to Investigate if Valproate Add-on Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
34 A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Adjunctive Lithium for the Treatment of Psychotic Mania Followed by an Open Label Long-term Safety Period. Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
35 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Lithium in Bipolar I Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
36 Pediatric Bipolar Collaborative Mood Stabilizer Trial Unknown status NCT00221429 Phase 3 lithium sodium divalproex
37 A Long-term Open-label Study of the Safety and Tolerability of Cariprazine in Patients With Bipolar I Disorder Completed NCT01059539 Phase 3 Cariprazine
38 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed NCT01986114 Phase 3 SM-13496
39 An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
40 An Open-Label Long-Term Study to Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents Completed NCT00195767 Phase 3 divalproex sodium
41 A 52-week, Open Label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750 - 2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00238485 Phase 3 Licarbazepine
42 A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With Bipolar I Disorder Completed NCT00114686 Phase 3 Quetiapine fumarate;lithium;divalproex
43 A Phase IIIb, Open Label Observational Study of SPD417 Used in Combination With Other Psychotropic Medications for the Treatment of Bipolar I Disorder Completed NCT00150605 Phase 3 Extended-release carbamazepine
44 A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder Completed NCT03287869 Phase 3 Brexpiprazole
45 Study SCA104779, an Evaluation of BW430C (Lamotrigine) Versus Placebo in the Prevention of Mood Episodes in Bipolar I Disorder Patients Completed NCT00550407 Phase 3 lamotrigine;Placebo
46 A Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of Cariprazine in Patients With Acute Mania Associated With Bipolar I Disorder Completed NCT01058096 Phase 3 Cariprazine;Placebo
47 A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01305408 Phase 3 Armodafinil;Placebo
48 Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3 olanzapine;haloperidol;placebo
49 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750- 2000 mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00228059 Phase 3 Licarbazepine
50 A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated) Completed NCT00227305 Phase 3 quetiapine fumarate

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

40
Brain, Cortex, Testes, Amygdala, Eye, Prefrontal Cortex, B Lymphoblasts

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 2204)
# Title Authors PMID Year
1
One-pot reaction for determination of Asenapine maleate through facile complex formation with xanthine based dye: Application to content uniformity test. 61
32450539 2020
2
Predictive factors of functional outcome in patients with bipolar I disorder: a five-year follow-up. 61
32553365 2020
3
Can network analysis shed light on predictors of lithium response in bipolar I disorder? 61
32068882 2020
4
Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. 61
32540496 2020
5
Bipolar Disorder Among Patients Diagnosed With Frontotemporal Dementia. 61
32498603 2020
6
Psychiatric Prodrome in Anti-NMDAR-Associated Encephalopathy: Clinical and Pathophysiologic Considerations. 61
32569449 2020
7
Lithium Use during Pregnancy and the Risk of Miscarriage. 61
32545238 2020
8
Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. 61
31628698 2020
9
Predictors of Depressive Switch in Patients With Bipolar I Disorder Who Initiated or Changed Pharmacologic Treatment for Mania or Mixed-Mania: A Prospective Observational Study. 61
32526106 2020
10
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study. 61
32004636 2020
11
Neural Subtypes of Euthymic Bipolar I Disorder Characterized by Emotion Regulation Circuitry. 61
32513391 2020
12
The tolerability and safety profile of eslicarbazepine acetate in neurological disorders. 61
32217376 2020
13
Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction. 61
32103459 2020
14
Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic. 61
32558403 2020
15
Cognitive Heterogeneity across Schizophrenia and Bipolar Disorder: A Cluster Analysis of Intellectual Trajectories. 61
32423506 2020
16
Stiff-person syndrome in a patient with comorbid bipolar and panic disorders: A case report and literature review. 61
32420007 2020
17
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study. 61
32393412 2020
18
Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. 61
32339131 2020
19
Psychosis, Mania and Criminal Recidivism: Associations and Implications for Prevention. 61
32251070 2020
20
Peripherally Physiological Responses to External Emotions and Their Transitions in Bipolar I Disorder With and Without Hypersexuality. 61
32133544 2020
21
Predictors of 1-year rehospitalization in inpatients with bipolar I disorder treated with atypical antipsychotics. 61
32459726 2020
22
Structural brain morphometry associated with theory of mind in bipolar disorder and schizophrenia. 61
31773921 2020
23
Shared and dissociable features of apathy and reward system dysfunction in bipolar I disorder and schizophrenia. 61
30994080 2020
24
162 Post-lithium Delirious Mania in Patients with Bipolar Disorder. 61
32331067 2020
25
Patterns and clinical correlates of lifetime alcohol consumption in women and men with bipolar disorder: Findings from the UK Bipolar Disorder Research Network. 61
32239612 2020
26
Facial emotion recognition deficits in patients with bipolar disorder and their healthy parents. 61
32361661 2020
27
Psychotic and affective symptoms of early-onset bipolar disorder: an observational study of patients in first manic episode. 61
31576937 2020
28
154 Functioning in de Novo and Rollover Patients with Bipolar I Disorder Receiving Aripiprazole Once-monthly in a 52-Week, Open-label Study. 61
32331008 2020
29
155 Symptom Stability in de Novo and Rollover Patients with Bipolar I Disorder Receiving Aripiprazole Once-monthly in a 52-Week, Open-label Study. 61
32331069 2020
30
160 Lurasidone and Metabolic Syndrome: Results from Short- and Long-Term Clinical Studies in Patients with Bipolar Depression. 61
32331053 2020
31
159 Safety and Efficacy of Lurasidone in Children and Adolescents with Bipolar Depression: Results from a 2-Year Open-label Extension Study. 61
32331016 2020
32
Manipulation ability of internal representation in patients with euthymic bipolar I disorder and schizophrenia using a mental rotation task. 61
32126521 2020
33
156 The Broad Efficacy of Cariprazine Across Symptoms in Patients with Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials. 61
32331052 2020
34
[Malignant neuroleptic syndrome: An atypical case in an adolescent affected by bipolar I disorder associated with catatonic syndrome]. 61
31522832 2020
35
145 Incidence and Characteristics of Akathisia and Restlessness During Cariprazine Treatment for Bipolar I Disorder. 61
32331021 2020
36
Improvement in cognitive function in young people with bipolar disorder: Results from participants in an 18-month randomised controlled trial of adjunctive psychotherapy. 61
31735057 2020
37
Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial. 61
32167792 2020
38
High Correspondence Between Child Behavior Checklist Rule Breaking Behavior Scale with Conduct Disorder in Males and Females. 61
32172405 2020
39
Relationship between Matrix Metalloproteinase-9 and Lifetime History of Suicidal Behavior in Remitted Patients with Bipolar I Disorder: A Cross-Sectional Pilot Study. 61
32346265 2020
40
Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post- hoc analysis of a randomized double-blind placebo-controlled trial. 61
31845587 2020
41
Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls 61
32096617 2020
42
Comorbid personality disorders in manic bipolar I disorder patients is associated with increased use of long-acting injectable antipsychotic treatment and higher rates of rehospitalization. 61
31764217 2020
43
Long-term impact of pharmacist intervention in patients with bipolar disorder: extended follow-up to the EMDADER-TAB study. 61
32072044 2020
44
Exploring the clinical utility of two staging models for bipolar disorder. 61
31449716 2020
45
The methods and baseline characteristics of a VA randomized controlled study evaluating supported employment provided in primary care patient aligned care teams. 61
32066380 2020
46
Symptom profile of postpartum and non-postpartum manic episodes in bipolar I disorder: a within-subjects study. 61
31981939 2020
47
Triazolam-induced Mania in a Patient with Bipolar I Disorder Following a Dental Procedure. 61
32257665 2020
48
Differences in outcomes between older community-dwelling patients with bipolar disorder and schizophrenia with illness onset at young age. 61
31975543 2020
49
Lithium Use in a Patient With Bipolar Disorder and End-Stage Kidney Disease on Hemodialysis: A Case Report. 61
32116831 2020
50
Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review. 61
30306873 2020

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

Pathways related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.9 HTR2C HTR2A DRD2 DRD1 CACNA1C BDNF
2
Show member pathways
12.69 DRD4 DRD3 DRD2 DRD1 CACNA1C BDNF
3
Show member pathways
12.53 PER3 DRD4 DRD3 DRD2 DRD1 COMT
4 12.42 KCTD12 HTR1A GAD1 DTNBP1 COMT ARNTL
5 12.23 DRD4 DRD3 DRD2 DRD1 CACNA1C
6 12.17 HTR1A DRD2 DRD1 CACNA1C BDNF
7
Show member pathways
12.16 HTR2C HTR2A DRD1 CACNA1C
9 12.05 SLC6A4 HTR2A HTR1A BDNF
10
Show member pathways
11.9 DRD2 DRD1 CACNA1C BDNF
11
Show member pathways
11.83 DRD4 DRD2 DRD1 CACNA1C
12 11.83 SLC6A4 HTR2C HTR2A HTR1A CACNA1C
13 11.78 HTR2A DRD4 DRD3
14
Show member pathways
11.76 DRD4 DRD3 DRD2
15 11.7 HTR2C HTR2A DRD2 DRD1
16
Show member pathways
11.54 HTR2C HTR2A HTR1A DRD4 DRD3 DRD2
17 11.07 SLC6A4 HTR2C HTR2A HTR1A
18 10.72 TIMELESS ARNTL
19 10.61 GADL1 GAD1
20
Show member pathways
10.53 SLC6A4 HTR1A DRD4 DRD3 DRD2 DRD1

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.31 SLC6A4 NRG1 KCTD12 HTR2C HTR2A HTR1A
2 cell GO:0005623 10.1 HTR2C HTR2A DRD4 DRD3 DRD2 DRD1
3 cell junction GO:0030054 10.05 SLC6A4 KCTD12 HTR2A DTNBP1 DRD1 CACNA1C
4 integral component of plasma membrane GO:0005887 10.02 SLC6A4 NRG1 HTR2C HTR2A HTR1A DRD4
5 postsynaptic membrane GO:0045211 9.88 KCTD12 DTNBP1 COMT CACNA1C ANK3
6 dendritic spine GO:0043197 9.83 DTNBP1 DRD2 DRD1 COMT
7 glutamatergic synapse GO:0098978 9.8 NRG1 HTR2A DTNBP1 DRD4 DRD3 DRD2
8 GABA-ergic synapse GO:0098982 9.76 NRG1 DRD3 DRD2 DRD1
9 axon GO:0030424 9.76 NRG1 HTR2A GAD1 DTNBP1 DRD2 COMT
10 sarcolemma GO:0042383 9.73 DTNBP1 CACNA1C ANK3
11 synaptic vesicle membrane GO:0030672 9.71 DTNBP1 DRD3 DRD2
12 integral component of presynaptic membrane GO:0099056 9.71 SLC6A4 HTR2A DRD2 DRD1
13 integral component of postsynaptic membrane GO:0099055 9.67 SLC6A4 HTR2A DRD2 DRD1
14 dendrite GO:0030425 9.65 HTR2C HTR2A HTR1A DRD4 DRD2 DRD1
15 dopaminergic synapse GO:0098691 9.55 DRD3 DRD2
16 synapse GO:0045202 9.44 SLC6A4 NRG1 KCTD12 HTR2C HTR2A HTR1A

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 HTR2C HTR2A HTR1A DRD4 DRD3 DRD2
2 G protein-coupled receptor signaling pathway GO:0007186 10.26 HTR2C HTR2A HTR1A DRD4 DRD3 DRD2
3 positive regulation of gene expression GO:0010628 10.12 SLC6A4 NRG1 DTNBP1 DRD1 ANK3
4 chemical synaptic transmission GO:0007268 10.07 HTR2C HTR2A HTR1A GAD1 DRD4
5 rhythmic process GO:0048511 10 TIMELESS PER3 DRD4 ARNTL
6 cellular calcium ion homeostasis GO:0006874 9.97 HTR2C HTR2A DRD4 DRD3
7 memory GO:0007613 9.95 SLC6A4 HTR2A DRD1 BDNF
8 synapse assembly GO:0007416 9.92 NRG1 DRD2 DRD1 BDNF
9 response to toxic substance GO:0009636 9.91 SLC6A4 DRD3 DRD2
10 circadian regulation of gene expression GO:0032922 9.91 PER3 DRD3 DRD2 ARNTL
11 regulation of synaptic vesicle exocytosis GO:2000300 9.9 HTR2A DTNBP1 DRD2 DRD1
12 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.89 DRD3 DRD2 DRD1
13 learning GO:0007612 9.89 DRD3 DRD1 COMT
14 locomotory behavior GO:0007626 9.89 NRG1 HTR2C DRD3 DRD2 DRD1
15 release of sequestered calcium ion into cytosol GO:0051209 9.88 HTR2C HTR2A DRD2
16 visual learning GO:0008542 9.88 DRD3 DRD2 DRD1
17 social behavior GO:0035176 9.88 SLC6A4 GAD1 DRD4 DRD3
18 circadian rhythm GO:0007623 9.88 TIMELESS SLC6A4 PER3 BDNF ARNTL
19 response to cocaine GO:0042220 9.87 DRD3 DRD2 DRD1
20 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.85 HTR2A HTR1A DRD4
21 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.85 HTR2C DRD3 DRD2 DRD1
22 negative regulation of protein secretion GO:0050709 9.84 DRD4 DRD3 DRD2
23 feeding behavior GO:0007631 9.84 HTR2C DRD2 DRD1 BDNF
24 arachidonic acid secretion GO:0050482 9.83 DRD4 DRD3 DRD2
25 temperature homeostasis GO:0001659 9.83 HTR2A DRD2 DRD1
26 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.83 DRD3 DRD2 DRD1
27 response to amphetamine GO:0001975 9.83 DRD4 DRD3 DRD2 DRD1
28 negative regulation of voltage-gated calcium channel activity GO:1901386 9.82 DRD4 DRD3 DRD2
29 prepulse inhibition GO:0060134 9.81 DRD3 DRD2 DRD1
30 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.81 HTR2A DRD3 DRD2
31 regulation of dopamine secretion GO:0014059 9.81 HTR2A DTNBP1 DRD3 DRD2
32 behavioral response to ethanol GO:0048149 9.8 DRD4 DRD3 DRD2
33 behavior GO:0007610 9.8 HTR2C HTR2A HTR1A
34 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.78 DRD3 DRD2 DRD1
35 regulation of potassium ion transport GO:0043266 9.77 DRD3 DRD2 ANK3
36 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.77 HTR2C HTR2A HTR1A DRD4 DRD1
37 regulation of dopamine metabolic process GO:0042053 9.75 HTR1A DRD4 DRD1
38 carboxylic acid metabolic process GO:0019752 9.74 GADL1 GAD1
39 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
40 vasoconstriction GO:0042310 9.74 SLC6A4 HTR1A
41 neurotransmitter biosynthetic process GO:0042136 9.74 SLC6A4 GAD1
42 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.74 DRD4 DRD3 DRD2
43 positive regulation of renal sodium excretion GO:0035815 9.73 DRD3 DRD2
44 grooming behavior GO:0007625 9.73 DRD2 DRD1
45 G protein-coupled receptor internalization GO:0002031 9.73 DRD3 DRD2
46 striatum development GO:0021756 9.73 DRD2 DRD1
47 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.73 DRD4 DRD3
48 inhibitory postsynaptic potential GO:0060080 9.73 DRD4 BDNF
49 serotonin receptor signaling pathway GO:0007210 9.73 HTR2C HTR2A HTR1A
50 dopamine receptor signaling pathway GO:0007212 9.73 DRD4 DRD3 DRD2 DRD1

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.45 TIMELESS SLC6A4 PER3 KCTD12 HTR2C HTR2A
2 G protein-coupled receptor activity GO:0004930 10.02 HTR2C HTR2A HTR1A DRD4 DRD3 DRD2
3 neurotransmitter receptor activity GO:0030594 9.73 HTR2C HTR2A HTR1A DRD4
4 drug binding GO:0008144 9.65 HTR2C HTR2A DRD4 DRD3 DRD2
5 G protein-coupled serotonin receptor activity GO:0004993 9.62 HTR2C HTR2A HTR1A DRD4
6 adrenergic receptor activity GO:0004935 9.58 DRD3 DRD2 DRD1
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.54 DRD4 DRD3 DRD2
8 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.46 HTR2C HTR2A
9 dopamine binding GO:0035240 9.46 DRD4 DRD3 DRD2 DRD1
10 serotonin binding GO:0051378 9.26 SLC6A4 HTR2C HTR2A HTR1A
11 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD4 DRD3 DRD2 DRD1

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....